HonCode

Go Back   HER2 Support Group Forums > Clinical Trials
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 11-05-2008, 10:41 AM   #1
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
BZL101 trial (oral botanical drug)

Trial
http://www.bzl101.com/

Info on drug and company
http://bionovo.com/pipeline/bzl101breastcancer
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Old 11-23-2008, 10:50 AM   #2
Rich66
Senior Member
 
Rich66's Avatar
 
Join Date: Feb 2008
Location: South East Wisconsin
Posts: 3,431
Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology EMERYVILLE, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced the company will present results from the Phase 1B clinical trial of their lead drug candidate for advanced metastatic breast cancer, BZL101, at the Society for Integrative Oncology's Fifth International Conference in Atlanta, Georgia. The Company's oral presentation was selected as a top scoring abstract and will be presented as a part of the Best of the SIO Session on November 20, 2008.
The Phase 1B clinical trial was conducted at seven US clinical sites under the directorship of Dr. Charles Shapiro, Professor of Medicine and Director of Breast Oncology at Ohio State University. The primary objective of the study was to identify the maximum tolerated dose of BZL101 and to determine the safety and feasibility of the company's novel, oral anticancer therapy. A total of 27 women with metastatic breast cancer were enrolled to the Phase 1B trial. To date, 48 women with advanced breast cancer have been treated with BZL101 in two early phase trials. Results from the Phase 1B trial show that BZL101 continues to be safe and well-tolerated, with early signs of clinical efficacy.
Seventeen of the twenty-seven participants in the Phase 1B clinical trial were evaluable according to the Response Evaluation Criteria in Solid Tumors (RECIST). Of these seventeen evaluable women, six were stable on study medication for greater than 90 days and three were stable on study medication for greater than 180 days. One active patient on the trial has been stable for 12 months with radiographic evidence of tumor shrinkage.
"We are eager to advance BZL101 to Phase 2 clinical testing as the drug continues to have an improved safety profile over more traditional chemotherapeutic agents, and shows encouraging clinical activity in a cohort of women who have been heavily, but unsuccessfully, pretreated for metastatic breast cancer," said Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo.
Overall compliance with study medication was excellent with 90% of prescribed doses taken. The most common side effects experienced by women in the Phase 1B clinical trial were mild diarrhea and nausea.
"We are encouraged by the results of the Company's second Phase 1 trial in women with advanced breast cancer," said Isaac Cohen, Chairman and CEO of Bionovo. "There are currently over 160,000 women in the United States living with advanced breast cancer who are eagerly awaiting an oral anticancer drug with minimal side effects and the ability to extend life without profoundly diminishing their quality of life. We believe BZL101 may be an important new anticancer agent because its biological selectivity allows the drug to kill cancer cells without affecting normal cells. This will lead to a dramatically lower side effect profile."
Phase 2 Clinical Trial
The Phase 2 clinical trial is currently enrolling 80 women diagnosed with advanced, measurable breast cancer who have received no more than two prior cytotoxic cancer therapies.
The trial is open at the following clinical sites under the directorship of the listed investigators:
Institution Site Principle Investigator
California Cancer Care Inc.,
Greenbrae/San Mateo, California Dr. Peter Eisenberg
Columbia Presbyterian Medical Center,
New York, New York Dr. Dawn Hershman
Comprehensive Cancer Center at Desert Regional
Medical Center, Palm Springs, California Dr. Gail Leichman
Duke University, Durham, North Carolina Dr. Gretchen Kimmick
Lynn Regional Cancer Center, Boca Raton, Florida Dr. Reshma Mahtani
MD Anderson, Houston, Texas Dr. Banu Arun
Memorial Cancer Institute, Hollywood, Florida Dr. Alejandra Perez
Montefiore Medical Center, Bronx, New York Dr. Tianhong Li
Ohio State University, Columbus, Ohio Dr. Ewa Mrozek
St. Vincent's Medical Center, New York, New York Dr. Paula Klein
University of California, San Francisco, California Dr. Hope Rugo
University of Chicago, Chicago, Illinois Dr. Gini Fleming
University of Miami, Miami, Florida Dr. Alberto Montero
University of Pittsburg Magee Women's Hospital,
Pittsburg, Pennsylvania Dr. Adam Brufsky
University of Southern California, Los Angeles,
California Dr. Agustin Garcia
University of Texas, Southwestern, Dallas, Texas Dr. Jenny Li

BZL101
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact. Normal cells depend primarily on the citric acid cycle (>85%) and very little on glycolysis (<7%) for energy production. Cancer cells depend largely on glycolysis (>85%) for energy production. BZL101 stops the production cycle of energy in cancer cells by inhibiting glycolysis. This leads to DNA damage and cell death in cancer cells while normal cells remain unharmed.
There are currently no effective therapeutic cures for advanced breast cancer and treatment is primarily aimed at palliation of symptoms as well as improving overall survival. Over 200,000 women in the United States are diagnosed with breast cancer each year and breast cancer is the second leading cause of cancer death in women. Although survival after breast cancer treatment is improving, there are still over 40,000 deaths per year due to the disease in the Unites States alone.
Bionovo, Inc.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
__________________

Mom's treatment history (link)
Rich66 is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off

Forum Jump


All times are GMT -7. The time now is 02:16 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007
free webpage hit counter